Navarro, AlbaClot Razquin, GuillemMartínez Trillos, AlejandraPinyol, MagdaJares Gerboles, PedroGonzález Farré, BlancaMartínez, DanielTrim, NicolaFernàndez Pascual, VerònicaVillamor i Casas, NeusColomer Pujol, DolorsCosta, DolorsSalaverria Frigola, ItziarMartín García, DavidErber, WendyLópez González, CristinaJayne, SandrineSiebert, ReinerDyer, Martin J. S.Wiestner, AdrianWilson, Wyndham H.Aymerich Gregorio, MartaLópez Guillermo, ArmandoSànchez, Àlex (Sànchez Pla)Campo Güerri, EliasMatutes, EstellaBeà Bobet, Sílvia M.2018-06-112018-06-112017-090390-6078https://hdl.handle.net/2445/122886B-cell chronic lymphoproliferative disorders (B-CLPD) encompass a group of hematologic tumors that often present with leukemic involvement.1 Their heterogeneity and the lack of relatively specific diagnostic markers for most of these diseases make their diagnosis challenging, especially in cases that only have blood involvement or when histology is not available. With the currently used immunophenotypic and molecular markers, around 10% of B-CLPD cases remain unclassifiable and are categorized as B-CLPD, not otherwise specified (B-CLPD, NOS).1 p.application/pdfeng(c) Ferrata Storti Foundation, 2017TumorsLeucèmiaTumorsLeukemiainfo:eu-repo/semantics/article6746932018-06-11info:eu-repo/semantics/openAccess28522579